Peripheral inflammation is associated with remote global gene expression changes in the brain

Journal of Neuroinflammation

Gerard J Graham¹  Jonathan Cavanagh²  Alison McColl¹  Carolyn A Thomson¹ 

[1] Institute of Infection, Immunity & Inflammation, College of Medical & Veterinary Life Sciences, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK;Institute of Health & Wellbeing, College of Medical & Veterinary Life Sciences, University of Glasgow, Southern General Hospital, Glasgow G51 4TF, UK

关键词: toll-like-receptor ligation;    systemic inflammation;    neuroinflammation;    neuroimmune communication;    lipopolysaccharide;    interferon-stimulated genes;    interferons;    innate immunity;    cytokines;   

Others  :  804842
DOI  :  10.1186/1742-2094-11-73

 received in 2013-12-12, accepted in 2014-03-11,  发布年份 2014

【 摘 要 】

Background

Although the central nervous system (CNS) was once considered an immunologically privileged site, in recent years it has become increasingly evident that cross talk between the immune system and the CNS does occur. As a result, patients with chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease or psoriasis, are often further burdened with neuropsychiatric symptoms, such as depression, anxiety and fatigue. Despite the recent advances in our understanding of neuroimmune communication pathways, the precise effect of peripheral immune activation on neural circuitry remains unclear. Utilizing transcriptomics in a well-characterized murine model of systemic inflammation, we have started to investigate the molecular mechanisms by which inflammation originating in the periphery can induce transcriptional modulation in the brain.

Methods

Several different systemic and tissue-specific models of peripheral toll-like-receptor-(TLR)-driven (lipopolysaccharide (LPS), lipoteichoic acid and Imiquimod) and sterile (tumour necrosis factor (TNF) and 12-O-tetradecanoylphorbol-13-acetate (TPA)) inflammation were induced in C57BL/6 mice. Whole brain transcriptional profiles were assessed and compared 48 hours after intraperitoneal injection of lipopolysaccharide or vehicle, using Affymetrix GeneChip microarrays. Target gene induction, identified by microarray analysis, was validated independently using qPCR. Expression of the same panel of target genes was then investigated in a number of sterile and other TLR-dependent models of peripheral inflammation.

Results

Microarray analysis of whole brains collected 48 hr after LPS challenge revealed increased transcription of a range of interferon-stimulated genes (ISGs) in the brain. In addition to acute LPS challenge, ISGs were induced in the brain following both chronic LPS-induced systemic inflammation and Imiquimod-induced skin inflammation. Unique to the brain, this transcriptional response is indicative of peripherally triggered, interferon-mediated CNS inflammation. Similar models of sterile inflammation and lipoteichoic-acid-induced systemic inflammation did not share the capacity to trigger ISG induction in the brain.

Conclusions

These data highlight ISG induction in the brain as being a consequence of a TLR-induced type I interferon response. As considerable evidence links type I interferons to psychiatric disorders, we hypothesize that interferon production in the brain could represent an important mechanism, linking peripheral TLR-induced inflammation with behavioural changes.

【 授权许可】

   
2014 Thomson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
• [2]Addolorato G, Capristo E, Stefanini GF, Gasbarrini G: Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997, 32:1013-1021.
• [3]Dickens C, McGowan L, Clark-Carter D, Creed F: Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002, 64:52-60.
• [4]Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R, Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2007, 367:29-35.
• [5]Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T: Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 β: a study on IL-6-deficient mice. J Exp Med 1996, 183:311-316.
• [6]Bluthé RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW, Dantzer R: Synergy between tumor necrosis factor α and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology 1994, 19:197-207.
• [7]Dantzer R: Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001, 15:7-24.
• [8]Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M: Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003, 64:708-714.
• [9]Kraus MR, Schäfer A, Schöttker K, Keicher C, Weissbrich B, Hofbauer I, Scheurlen M: Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008, 57:531-536.
• [10]Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K: Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999, 156:1120.
• [11]Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
• [12]Neilley LK, Goodin DS, Goodkin DE, Hauser SL: Side effect profile of interferon beta-lb in MS: results of an open label trial. Neurology 1996, 46:552-553.
• [13]Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
• [14]How to Design a Successful Microarray Experiment [http://www.brc.dcs.gla.ac.uk/~rb106x/microarray_tips.htm webcite]
• [15]van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
• [16]Glasgow Polyomics: Glasgow Polyomics. [http://www.gla.ac.uk/colleges/mvls/researchinstitutes/gpf webcite]
• [17]DAVID Bioinformatics Resources 6.7 [http://david.abcc.ncifcrf.gov/ webcite]
• [18]Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protocols 2008, 4:44-57.
• [19]Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37:1-13.
• [20]Ingenuity® [http://www.ingenuity.com webcite]
• [21]McKimmie CS, Fazakerley JK: In response to pathogens, glial cells dynamically and differentially regulate toll-like receptor gene expression. J Neuroimmunol 2005, 169:116-125.
• [22]Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci 2007, 104:16239-16244.
• [23]Nadeau S, Rivest S: Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood–brain barrier. Neuroscience 1999, 93:1449-1464.
• [24]Quan N, Whiteside M, Herkenham M: Time course and localization patterns of interleukin-1β messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience 1998, 83:281-293.
• [25]Buttini M, Boddeke H: Peripheral lipopolysaccharide stimulation induces interleukin-1β messenger RNA in rat brain microglial cells. Neuroscience 1995, 65:523-530.
• [26]Serrats J, Schiltz JC, García-Bueno B, van Rooijen N, Reyes TM, Sawchenko PE: Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron 2010, 65:94-106.
• [27]Liew FY, Xu D, Brint EK, O’Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005, 5:446-458.
• [28]Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
• [29]Chen R, Zhou H, Beltran J, Malellari L, Chang SL: Differential expression of cytokines in the brain and serum during endotoxin tolerance. J Neuroimmunol 2005, 163:53-72.
• [30]Faggioni R, Fantuzzi G, Villa P, Buurman W, van Tits LJ, Ghezzi P: Independent down-regulation of central and peripheral tumor necrosis factor production as a result of lipopolysaccharide tolerance in mice. Infect Immun 1995, 63:1473-1477.
• [31]Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
• [32]Nakajima K, Kanda T, Takaishi M, Shiga T, Miyoshi K, Nakajima H, Kamijima R, Tarutani M, Benson JM, Elloso MM, Gutshall LL, Naso MF, Iwakura Y, DiGiovanni J, Sano S: Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011, 186:4481-4489.
• [33]Skelly DT, Hennessy E, Dansereau MA, Cunningham C: A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1β, TNF-α and IL-6 challenges in C57BL/6 mice. PLoS One 2013, 8:e69123.
• [34]Leung PY, Stevens SL, Packard AE, Lessov NS, Yang T, Conrad VK, van den Dungen NN, Simon RP, Stenzel-Poore MP: Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. Stroke 2012, 43:1383-1389.
• [35]Banks WA, Robinson SM: Minimal penetration of lipopolysaccharide across the murine blood–brain barrier. Brain Behav Immun 2010, 24:102-109.
• [36]Laflamme N, Soucy GV, Rivest S: Circulating cell wall components derived from Gram-negative, not Gram-positive, bacteria cause a profound induction of the gene-encoding Toll-like receptor 2 in the CNS. J Neurochem 2001, 79:648-657.
• [37]Field R, Campion S, Warren C, Murray C, Cunningham C: Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNα/β and IL-1β responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 2010, 24:996-1007.
• [38]Konat GW, Borysiewicz E, Fil D, James I: Peripheral challenge with double-stranded RNA elicits global up-regulation of cytokine gene expression in the brain. J Neurosci Res 2009, 87:1381-1388.
• [39]Damm J, Wiegand F, Harden LM, Gerstberger R, Rummel C, Roth J: Fever, sickness behavior, and expression of inflammatory genes in the hypothalamus after systemic and localized subcutaneous stimulation of rats with the toll-like receptor 7 agonist Imiquimod. Neuroscience 2012, 201:166-183.